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ACTH-dependent hypercortisolism caused by a pituitary adenoma [Cushing’s disease 
(CD)] is the most common cause of endogenous Cushing’s syndrome. CD is often 
associated with several morbidities, including hypertension, diabetes, osteoporosis/
bone fractures, secondary infections, and increased cardiovascular mortality. While 
the majority (≈80%) of the corticotrophinomas visible on pituitary magnetic resonance 
imaging are microadenomas (MICs, <10 mm of diameter), some tumors are macroade-
nomas (MACs, ≥10 mm) with increased growth potential and invasiveness, exceptionally 
exhibiting malignant demeanor. In addition, larger and invasive MACs are associated 
with a significant increased risk of local complications, such as hypopituitarism and 
visual defects. Given the clinical and molecular heterogeneity of corticotrophinomas, 
the aim of this study was to investigate the pattern of genetic differential expression 
between MIC and MAC, including the invasiveness grade as a criterion for categorizing 
these tumors. In this study, were included tumor samples from patients with clinical, 
laboratorial, radiological, and histopathological diagnosis of hypercortisolism due to an 
ACTH-producing pituitary adenoma. Differential gene expression was studied using an 
Affymetrix microarray platform in 12 corticotrophinomas, classified as non-invasive MIC 
(n = 4) and MAC (n = 5), and invasive MAC (n = 3), according to modified Hardy criteria. 
Somatic mutations in USP8 were also investigated, but none of the patients exhibited 
USP8 variants. Differential expression analysis demonstrated that non-invasive MIC 
and MAC have a similar genetic signature, while invasive MACs exhibited a differential 
expression profile. Among the genes differentially expressed, we highlighted CCND2, 
ZNF676, DAPK1, and TIMP2, and their differential expression was validated through 
quantitative real-time PCR in another cohort of 15 non-invasive and 3 invasive corto-
cotrophinomas. We also identified potential biological pathways associated with growth 
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inTrODUcTiOn
ACTH-dependent hypercortisolism caused by a pituitary 
adenoma [Cushing’s disease (CD)] is the most common cause 
of endogenous Cushing’s syndrome, representing ≈10% of all 
pituitary adenomas (1, 2). CD is often associated with several 
morbidities, including hypertension, diabetes, osteoporosis/bone 
fractures, secondary infections, and increased cardiovascular 
mortality (3–5). The severity of the clinical manifestations varies 
according to the level of hormonal overproduction, exposure 
time, and glucocorticoid receptors sensitivity. While the major-
ity of the corticotrophinomas visible on pituitary magnetic 
resonance imaging (MRI) are microadenomas (MICs, <10 mm 
of diameter), some macroadenomas (MACs, ≥10  mm) exhibit 
increased growth potential and invasiveness, exceptionally exhib-
iting malignant behaviour (6–9). In addition, larger and invasive 
MACs are associated with a significant increased risk of local 
complications, such as hypopituitarism and visual loss (6, 8, 10).
It has been reported that the persistence of cortisol response 
to desmopressin, in the early postoperative period, could help 
to identify CD patients with initial remission, who present risk 
for later recurrence (11). However, apart from clear radiological 
signs of invasiveness, strong predictors of poor surgical outcomes 
are not available and early predictors of tumor growth and inva-
siveness would be of clinical value.
Over the years, molecular markers have emerged as potential 
predictors of tumor aggressiveness. Previously, the overexpres-
sion of fibroblast growth factor receptor-4 (FGFR4) was correlated 
with the proliferation marker Ki-67 and tended (but not sig-
nificantly) to be found in invasive pituitary adenomas (12). Also, 
we have suggested that increased FGFR4 expression levels and 
the presence of homozygosis for the FGFR4 Gly388 allele were 
associated with a higher frequency of postoperative recurrence 
and persistence of CD, respectively (13). Evidence suggests that 
the signaling properties of N-cadherin, with particular emphasis 
on its cross talk with cell surface partners such as FGFR4 and 
NCAM, are important in pituitary tumorigenesis (1, 7, 14, 15). 
The potential oncogenic contribution of fibroblast growth factors 
and their receptors to pituitary tumorigenesis and invasiveness 
is still unclear, although it is well established that these growth 
factors and respective receptors are important for a variety of 
biological processes, including mitogenesis, differentiation, 
development, angiogenesis, and tumorigenesis (16).
Recently, Reincke et al. (17) identified somatic heterozygous 
mutations in USP8 (ubiquitin-specific protease Y), an important 
regulator of the epidermal growth factor receptor (EGFR) down-
stream signaling, in ≈36% of corticotrophinomas. Noteworthy, 
the majority of the cases with USP8 mutations were MICs from 
young patients with CD (17, 18). The authors suggest that in the 
presence of such mutations, EGFR ubiquitination, and turnover 
would be impaired, causing its accumulation in the plasma 
membrane, where the receptor remains active and stimulating 
proopiomelanocortin transcription and ACTH secretion and 
also contributing to corticotrophic tumorigenesis (17). However, 
in these studies, the authors did not study any invasive cortico-
troph tumor.
Lately, a review has collected data from studies of gene and 
protein expression in corticotrophinomas, compared to normal 
pituitary gland, with the aim of prioritizing targets that could 
contribute to the improvement of the molecular diagnosis of 
CD. Among the differentially expressed genes and respective 
proteins in corticotrophinomas, the most well-established 
candidates, emphasized in multiple studies, were NEUROD1 
(neuroD1), hPTTG1 (securin), HSD11B2 (11β-hydroxysteroid 
dehydrogenase 2), AKT (Akt protein kinase B), CCND1 (cyclin 
D1) (overexpressed), CDKN1B (p27Kip1), CDKN2A (p16), KISS1 
(kisspeptin), and ACTHR (ACTH-R) (underexpressed) (19).
hPTTG1 is a member of the securin family, which regulates 
sister chromatid separation during mitosis. Evidence suggests 
tissue-specific expression of three hPTTG1 genes and potential 
roles for each of them in tumorigenesis, cell transformation, 
DNA repair, angiogenesis, and gene regulation (20). It is note-
worthy that it has already been demonstrated that increased 
hPTTG1 expression was associated with invasiveness in 
functional pituitary adenomas (21). This overexpression was 
not only observed in pituitary adenomas but also in various 
non-pituitary and pituitary carcinoma, at even higher levels 
(21, 22), and these data contributed to hPTTG1 being classified as 
a proto-oncogene. Years later, Filippella et al. (23) demonstrated 
a positive correlation between hPTTG1 expression and the Ki-67 
nuclear proliferation index, with the expression, aggressiveness, 
invasiveness, and recurrence potential of pituitary adenomas.
According to the clinical and molecular heterogeneity of 
corticotrophinomas, we aimed to explore the pattern of gene 
expression associated with tumor growth and invasiveness. 
Therefore, we studied a cohort of corticotrophinomas, with dif-
ferent phenotypic features, by microarray analysis.
sUBJecTs anD MeThODs
Patients and Tumor samples
Fifteen subjects (14 females and 1 male—age ranged between 
14–70 years) with clinical, laboratorial, radiological, and histo-
pathological diagnosis of ACTH-producing pituitary adenoma 
were included in this study.
and invasiveness, TGF-β and G protein signaling pathways, DNA damage response 
pathway, and pathways associated with focal adhesion. Our study revealed a differential 
pattern of genetic signature in a subgroup of MAC, supporting a genetic influence on 
corticotrophinomas in patients with CD.
Keywords: cushing’s disease, gene expression, neuroendocrine tumors, microarray, anterior pituitary
TaBle 1 | Patients with cushing’s disease included to microarray study.
iD gender age (years) grade size (mm) Uc 50–310 μg/24 h acTh < 46 pg/ml invasion remission Ki-67 p53
non-invasive microadenomas
1 F 39 I 6 610 38 Absent No 2% 1%
2 F 41 I 6 572 39 Absent No 2% 1%
3 F 32 I 7 388 54 Absent Yes NA NA
4 F 39 I 8 961 63 Absent Yes NA NA
non-invasive Macs
5 F 70 II 15 269 46 Absent No 1% 1%
6 F 36 II 12 1,390 53 Absent Yes NA NA
7 F 28 II 20 326 26 Absent Yes 2% NA
8 F 47 II 11 925 79 Absent Yes 1% 1%
9 F 14 II 19 1,207 68 Absent Yes 2% NA
invasive Macs
10 F 43 III 25 445 150 RCS No 1% 1%
11 F 30 IV 40 378 46 LCS No 1% 2%
12 F 50 IV 18 395 111 RCS No 1% 1%
Non-invasive adenomas were classified according to Hardy (6) modified by Wilson (27), and invasive MACs were classified according to Knosp et al. (28). Total urinary cortisol 
was measured without extraction. The mean follow-up was 24 months. ID, patient number; UC, urinary cortisol, mean of three or more samples; NA, data not available; RCS, right 
cavernous sinus; LCS, left cavernous sinus; MACs, macroadenomas.
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Diagnosis of ACTH-dependent Cushing’s syndrome was 
based on typical clinical features and standard hormonal crite-
ria: increased 24-h urinary cortisol excretion, loss of circadian 
rhythm of cortisol secretion (increase of nocturnal serum cortisol 
and/or nocturnal salivary cortisol), lack of suppression of serum 
cortisol after a low-dose dexamethasone test (1 mg orally over-
night), and elevated or inappropriate normal plasma ACTH levels 
(>15 pg/mL) (24, 25).
Ethical approval was obtained from the institutional review 
boards of Institution (Comissao de Etica para Analise de Projetos 
de Pesquisa—CAPPesq), and informed consent was obtained 
from all participants in written form and in accordance with the 
Declaration of Helsinki.
Tumoral tissue specimens were obtained during transsphe-
noidal surgery. Tissue portions not used for histology and were 
snap-frozen in liquid nitrogen, preceding RNA/DNA extraction 
(AllPrep DNA/RNA kit®—Qiagen GmbH, Hilden, Germany). 
After extraction, quality (A260/A280 A260/A280 acceptable ratio 
range of 1.8–2.0) and integrity were assessed by absorbance meas-
ures in a NanoDrop™ spectrophotometer (Thermo Scientific) 
and agarose gel electrophoresis.
Tumor characterization
Corticotroph tumors were characterized by immunostaining 
for ACTH. Tumor size and invasiveness were defined based on 
preoperative pituitary MRI and perioperative findings (26). We 
adopted the modified Hardy, as follows: grade I, enclosed MIC 
(tumor <10 mm); grade II, enclosed MAC (tumor ≥10 mm); 
grade III, localized perforation of the sellar floor; and grade 
IV, diffuse destruction of the sellar floor (6, 27). Grade III and 
IV adenomas were considered invasive, and tumor invasion 
was based on the evidence of bone destruction and/or tumor 
extension within sphenoid and/or cavernous sinuses and/
or brain, as confirmed at surgery (28, 29). In our cohort, the 
immunohistochemical markers for aggressiveness: elevated 
Ki-67 (>3%) and increased nuclear reaction for the p53 protein 
were not observed in both non-invasive and invasive group of 
corticotrophinomas that underwent immunohistochemistry 
analysis (Table 1).
We assessed the degree of contamination with normal pituitary 
tissue by measuring the expression levels of POU1F1 and TPIT 
(the genes encoding the transcription factors Pit-1 and T-pit) 
as previously described by our group (13). Corticotrophinomas 
should exhibit high levels of TPIT expression and undetectable 
levels of POU1F1. On the other hand, POU1F1 expression levels 
are significantly higher in the normal pituitary, since it is expressed 
by all the pituitary cell lineages, except the corticotrophic. After 
PCR analysis, 3 of our 15 primary samples were excluded, due 
to visible POU1F1 expression, indicating possible contamina-
tion with normal pituitary tissue (Figure S1 in Supplementary 
Material).
Demographic and clinical characteristics of the remaining 
participants are summarized in Table 1.
UsP8 analysis
As somatic mutations were recently described in the literature 
(17), we also performed a mutational analysis of the ubiquitin-
specific protease 8 (USP8; Ensembl: ENSG00000138592) to 
investigate its presence/incidence in our cohort. It was accom-
plished using PCR amplification by specific primers (Table S1 in 
Supplementaary Material) and automatic SANGER sequencing 
according to Perez-Rivas et al. (18) in DNA extracted of patients 
tumors.
Microarray analysis
We extracted total RNA from four MICs (mean tumor size 
6.75 ± 0.96 mm), five MACs (mean tumor size 15.40 ± 4.04 mm), 
and three invasive corticotrophinomas (mean tumor size 
27.67 ± 11.24 mm).
Microarray mRNA expression profiling was performed 
using the Affymetrix Human Exon 1.0 ST® chip (Affymetrix, 
Inc., Santa Clara, CA, USA). The mRNA was amplified into 
TaBle 2 | characteristics of the gene probes used in quantitative real-
time Pcr.
gene symbol Description assay
TBP (housekeeping) TATA-box binding protein 4326322E
CCND2 Cyclin D2 HS00153380_M1
ZNF676 Zinc-finger 676 protein HS00234278_M1
DAPK1 Death-associated protein kinase 1 HS05234480_M1
TIMP2 TIMP metalloproteinase inhibitor 2 HS01939480_S1
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single-stranded-cDNA, fragmented, biotin-labeled, and 
hybridized to a chip using the Gene Chip® WT Plus Reagent 
Kit (Affymetrix) according to the standard manufacturer’s 
protocols.
Raw microarray data were acquired using Affymetrix 
GeneChip operating software (GCOS) (Affymetrix) to yield CEL 
files. The success of hybridization was evaluated, and data were 
processed and analyzed using Affymetrix Expression Console® 
1.3 (Affymetrix) and gene level differential analysis workflow of 
Transcriptome Analysis Console® 3.1 (Affymetrix). The back-
ground subtraction, normalization, and log base 2 transforma-
tion of gene signals were conducted using the robust multi-array 
average algorithm (30).
Differentially expressed genes were determined by comparing 
the groups MIC, MAC, and/or invasive using one-way ANOVA 
(p-value <0.05). Additionally, gene expression was compared by 
grouping tumors into non-invasive (n = 9) and invasive (n = 3). A 
Benjamini–Hochberg multiple testing correction adjusted p-value 
to smaller than 0.05, in addition a twofold change were used to 
select genes differentially expressed (31) (annotation file: HuEx-
1_0-st-v2.na33.1.hg19.transcript.csv). Hierarchical clustering of 
the expression data was performed using the Euclidean distance 
metric and complete linkage method. Functional annotation 
was performed using DAVID1 and Enrich.2 Raw and normal-
ized data of microarray analysis reported here were deposited 
in Gene Expression Omnibus database under accession number 
GSE72490.
Quantitative real-time Pcr (qrT-Pcr) 
analysis
A subset of four target genes and was tested by qRT-PCR, and the 
assays are summarized in Table 2.
In order to perform data validation, we designed an addi-
tional cohort of 18 patients for this analysis; 5 patients from 
Neuroendocrinology Unit of Hospital das Clinicas of University 
of São Paulo Medical School and 13 from the Ribeirao Preto 
Medical School. These patients were selected and classified 
according to the same criteria described in the Section “Patients 
and Tumor Samples.” Demographic and clinical characteristics 
of the individuals, divided into invasive (n  =  3) and non-
invasive (n = 15) groups, are summarized In Table 3. Similar 
to our initial cohort, USP8 mutations were also investigated in 
these patients.
Quantitative RT-PCR used TaqMan Universal PCR Master 
Mix and was run on an ABI 7000 Sequence Detection Systems® 
(Applied Biosystems, Foster City, CA, USA). Each reaction was 
performed with 2.0 μL cDNA (obtained from 5 ng of total RNA). 
Each target gene was normalized to the Tata-box binding protein 
gene (TBP), as previously standardized in our laboratory (32). 
Gene expressions values were calculated with the 2−∆∆Ct method, 
where the ΔCt value of the sample was determined by subtracting 
the average Ct value of the target gene from the average Ct value 
of the housekeeping gene. We used as a calibrator a commercial 
1 https://david.ncifcrf.gov/home.jsp.
2 http://amp.pharm.mssm.edu/Enrichr/.
pool of normal pituitary gland (Pituitary Gland Human Poly 
A + RNA, Clontech, Japan).
resUlTs
Before microarray analysis, we performed the screening for 
mutations in USP8 in our patients, and it did not reveal any 
pathogenic variants.
Differentially expressed genes
Using Transcriptome Analysis Console (Affymetrix) software, 
a fold change and intensity-based filtering approach (>2.0-fold 
change and ANOVA p < 0.05) demonstrated only 48 transcripts 
differentially expressed in the MAC group compared to the 
MIC group: 41 transcripts were relatively overexpressed and 
7 were underexpressed (Table  4). However, the hierarchical 
clustering analysis did not reveal differences that could success-
fully distinguish these groups (data not shown). In comparing 
corticotrophinomas grouped into invasive and non-invasive 
tumors, we observed 748 differentially expressed transcripts: 396 
overexpressed and 352 underexpressed.
After that, we applied a false discovery rate (FDR) cutoff of 
0.05 to obtain a robust list of 168 differentially expressed genes 
(Table  5; Table S2 in Supplementary Material; Figure  1A), in 
which downregulation was the most prevalent feature (n = 150). 
A heat map and hierarchical cluster of these 168 genes clearly 
demonstrated a different gene expression signature between 
invasive and non-invasive groups (Figure 2).
Figure  1B demonstrates the transcriptomic data between 
invasive and non-invasive corticotrophinomas, indicating some 
genes that will be properly discussed later in this paper. Some of 
the differentially expressed genes have known functions in cancer, 
cell cycle, and death (overexpressed: CCND2; underexpressed: 
DAPK1, CDKN2A), transcription factor, and gene expression 
regulation (overexpressed: ZNF676), cellular homeostasis, adhe-
sion, and motility (overexpressed: KCNH8, DHCR24, MGARP, 
PRKD3; underexpressed: DOCK11, SPON1, SEPT3), and protein 
binding (underexpressed: TIMP2).
A list of 20 most significantly and functionally relevant 
genes differentially expressed between these groups is shown in 
Table 6.
Further, to analyze the biological significance of these genes, 
we used DAVID and Enrich chip annotation tools to reveal the 
functional description, classification, and location of the dif-
ferentially expressed genes. The annotation results showed that 
of the 168 differentially expressed genes, 92 were known genes 
TaBle 3 | Patients with cushing’s disease included to the validation study using quantitative real-time Pcr.
iD gender age (years) grade size (mm) nsc < 0.12 μg/dl acTh < 46 pg/ml invasion
non-invasive corticotrophinomas
2339 F 47 I 2 1.3 90.5 Absent
1138 F 54 I 3 1.6 53.3 Absent
2341 F 35 I 3 1.3 70.5 Absent
2337 F 27 I 5 2.0 95.2 Absent
2336 F 43 I 5 1.3 51.3 Absent
2332 F 23 I 5 1.6 35.9 Absent
2338 F 14 I 6 4.0 46.3 Absent
175 F 42 I 7 0.5 81.1 Absent
97 F 23 II 7 0.8 39.0 Absent
1132 F 45 II 10 2.3 73.9 Absent
2335 F 44 II 10 3.3 58.3 Absent
2330 F 47 II 12 17.8 128 Absent
1154 F 36 II 20 2.1 48.9 Absent
2331 F 31 II 20 1.9 118 Absent
1421 F 17 II 36 3.9 50.5 Absent
invasive corticotrophinomas
72 F 50 IV 18 0.08 66.0 RCS
169 F 40 III 25 0.08 83.6 RCS
160 F 59 IV 52 Not available 99.7 RCS
Non-invasive adenomas were classified according to Hardy (6) modified by Wilson (27), and invasive macroadenomas were classified according to Knosp et al. (28).
ID, patient number; NSC, nocturnal salivary cortisol; RCS, right cavernous sinus.
TaBle 4 | Differentially expressed genes in macro versus 
microcorticotrophinomas.
gene symbol Fold change 
(linear)
gene symbol Fold change (linear)
BMPR1B −4.92 FLJ38379 2.49
KCNK1 −3.66 JUN 2.52
CCDC144A −2.43 MLLT6 2.58
SV2B −2.39 GDA 2.63
TLR6 −2.11 PDE4D 2.67
KLHL1 −2.1 FXYD1 2.71
CSH2 −2.04 BTBD11 2.71
C11orf63 2.01 FXYD3 2.73
LIN7A 2.01 UQCRFS1 2.81
DBN1 2.05 TGM2 2.82
PDGFC 2.09 STMN4 2.88
PDGFD 2.16 MT1G 3.20
KCNAB2 2.21 SLC7A5 3.36
DLG2 2.21 S1PR1 3.37
RPF2 2.22 CNR1 3.41
MC4R 2.23 TUBB2B 3.47
CTGF 2.32 MARCH1 3.54
ID 3402978 2.32 LYPD6B 3.56
SRP14 2.33 SCGB2A1 3.69
ID 2763154 2.38 ALDH1A1 3.76
PITPNM2 2.40 EFNA3 3.81
HLA-DOB 2.40 LOC100653008 4.88
CLVS1 2.42 ACSS3 5.20
ZNF208 2.43 TRPC7 12.62
ANOVA p-value <0.05; fold change cut off = 2; ID, transcript ID, no gene symbol 
available.
5
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associated with a diverse set of biological pathways. Among these 
pathways, nine showed altered expression of at least three genes 
(Table 7). They include the TGF-β and G protein signaling path-
ways, DNA damage response pathway, and pathways associated 
with focal adhesion.
Quantitative gene expression analysis
Based on the degree of over- or underexpression in invasive versus 
non-invasive corticotrophinomas, expression of four genes was 
quantified by qRT-PCR. This analysis confirmed the overexpres-
sion of CCND2 (mean increase of 20.57-fold in invasive and 4.01-
fold in non-invasive, in relation to calibrator) and ZNF676 (mean 
increase of 5.13-fold in invasive and 2.04-fold in non-invasive, in 
relation to calibrator), and the underexpression of DAPK1 (mean 
increase of 0.18-fold in invasive and 3.3-fold in non-invasive, in 
relation to calibrator). Regarding to TIMP2, it was possible to 
observe only a tendency to underexpression (mean increase of 
0.85 times in invasive and 1.16 times in non-invasive, in relation 
to calibrator) (Figure 3).
Regarding to somatic USP8 mutations, they were identified in 
5 (non-invasive corticotrophinomas) out of 18 patients (27.7%) 
of validation cohort.
DiscUssiOn
In the microarray study cohort, we did not identify any USP8 
mutations. According to Reincke et  al. (17) and Perez-Rivas 
et al. (18), these mutations occur in ≈36% of patients with CD. 
As our microarray cohort was relatively small, it might explain 
the absence of USP8 mutations. However, in the patients 
included in the validation study, we could identify somatic 
USP8 mutations in 5 (non-invasive corticotrophinomas) out 
TaBle 5 | Differentially expressed genes in invasive versus non-invasive corticotrophinomas.
gene symbol Fold change gene symbol Fold change gene symbol Fold change gene symbol Fold change
IFI44 43.02 GPNMB 2.76 JAKMIP1 −2.29 ADD2 −3.54
ZNF676 29.28 VSIG1 2.76 JPH3 −2.29 TCF7L2 −3.59
CCND2 27.61 SLC39A8 2.75 FAXC −2.31 MYCN −3.73
ANGPTL7 15.2 IRAK4 2.59 CCDC88A −2.33 C14orf132 −3.94
ZNF208 13.55 BBS10 2.58 CERCAM −2.33 GNAO1 −3.95
ABRACL 11.87 TMEM63A 2.52 NAP1L5 −2.36 DACH2 −4.04
ALDH1A1 10.95 TLCD1 2.51 PRPF19 −2.39 LONRF2 −4.05
KCNH8 10.36 TMEM55A 2.34 CLIP4 −2.45 FXYD5 −4.09
MGARP 8.7 MIOS 2.33 CAMK1 −2.46 CAMKV −4.1
SLC7A2 7.35 CRLS1 2.28 ID 2622970 −2.49 SULT4A1 −4.16
KIAA0040 7.11 FER 2.26 KIF5A −2.5 KCNIP2 −4.26
CA10 7.06 ASPH 2.23 MAGEE1 −2.51 DKK3 −4.28
DHCR24 6.87 EFHA2 2.22 RXRA −2.57 PTPRJ −4.29
PRKD3 6.81 ZFYVE16 2.2 ARNT2 −2.61 SCN1B −4.29
CCL28 6.43 BRD9 2.19 BAIAP3 −2.62 CALY −4.33
CDKN1B 5.87 MTRF1 2.19 AKAP12 −2.68 CD200 −4.56
BDH2 5.8 WDYHV1 2.17 SCAMP5 −2.69 DTX1 −4.66
CEP85L 5.77 ZDHHC11 2.16 SLC4A3 −2.69 ID 2667243 −4.67
CALML4 5.55 SMC6 2.15 DGKH −2.7 SLC1A2 −4.88
SCML1 5.33 ADAM28 2.1 CCDC136 −2.71 DIRAS1 −4.97
SLC28A3 5.11 RBAK 2.06 RIMBP2 −2.74 RYR2 −5.5
STK3 4.78 BRCC3 2.05 CNNM1 −2.75 TUBB4A −5.52
FAM13A 4.25 TGS1 2.05 GABBR1 −2.76 ELMOD1 −5.75
INPP5J 4.24 GGCT 2.04 STARD10 −2.79 FGD5 −6.16
PDLIM1 4.14 CDKN2A −2.01 EIF4E3 −2.8 TAGLN3 −6.39
SLC43A1 4.14 PRKACB −2.02 TMEM54 −2.81 RGS7 −6.48
ZNF680 3.79 ID 615892 −2.07 KLHL23 −2.94 DOCK11 −7.17
PON2 3.71 KCNB1 −2.08 N4BP2L1 −2.95 ATCAY −7.18
NUPR1 3.63 KIF3C −2.09 PHOSPHO2-KLHL23 −2.96 KCND3 −7.65
PEX2 3.57 PIGZ −2.1 ECE2 −3.01 DAPK1 −7.8
SEPP1 3.36 NGFRAP1 −2.11 NISCH −3.03 CSGALNACT1 −8.2
NIN 3.23 MEF2A −2.12 SYT7 −3.03 CAV1 −9.03
CARD16 3.11 FAM19A5 −2.14 CRAT −3.04 NAALAD2 −9.34
PAQR8 3.05 RAB15 −2.14 GPRASP1 −3.04 MPPED2 −9.51
FCHO2 3.02 RUNDC3A −2.15 KIAA0930 −3.04 ELAVL3 −9.7
SLC25A13 3.02 TMEM179 −2.17 NAP1L3 −3.06 GHSR −10.13
CYP39A1 3 PDK2 −2.2 TIMP2 −3.07 ID 3063035 −10.29
SLC16A9 2.96 KIF6 −2.23 GPRASP2 −3.26 PPP1R17 −10.81
STK35 2.93 CELF6 −2.26 FAM171B −3.29 SEPT3 −11.83
FAS 2.91 SNCB −2.26 FAIM2 −3.3 C11orf87 −19.63
AP1G2 2.89 AGBL4 −2.27 FHL1 −3.33 VAT1L −23.83
CA13 2.82 ID 933392 −2.28 RAPGEF4 −3.33 SEZ6L −49.33
ANOVA p-value <0.05; fold change cut off = 2; false discovery rate <0.05; ID, transcript ID, no gene symbol available.
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of 18 patients (27.7%). Interestingly, the presence of USP8 
mutations did not interfere in the validation of the microarray 
expression study.
Our study design was original as we compared the gene 
expression profile of MIC and MAC, also considering tumoral 
invasiveness. Previous microarray studies have identified genes 
FigUre 1 | Transcriptomic data between invasive and non-invasive corticotrophinomas. (a) Scatter plot. (B) Volcano plot. The over- and underexpressed 
genes are represented in red and green, respectively. In these plots, genes with a fold change less than 2 and ANOVA p-value >0.05 are shown in light gray (in the 
center). The dashed red-line shows where false discovery rate (FDR) = 0.05, with points above the line having p < 0.05. Arrows highlights some genes discussed in 
the text.
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differentially expressed in pituitary adenomas including cortico-
trophinomas, but without taking into account their tumor size 
classification and/or invasiveness (33–35).
Despite our analysis did not show a clear functional distinction 
between MAC and MIC groups, we were able to identify genes 
selectively over- and underexpressed in the MAC invasive group, 
which exhibited a distinct gene expression signature from MIC 
and non-invasive MAC corticotrophinomas. Among the most 
differentially expressed genes, we highlighted CCND2 (cyclin D2) 
and ZNF676 (zinc-finger protein 676), which were increased by 
27- and 29-fold, respectively, DAPK1 and TIMP2 which was 
decreased by 8-fold and 3-fold, respectively.
CCND2 is a crucial cell cycle-regulatory protein; its overex-
pression is described in several human neoplasms, including 
colorectal adenomas and gastric cancer, and it is associated with 
a poor prognosis in gastric cancer (36). Genetic aberrations of 
CCND2 are also frequently described in gliomas and hematologic 
malignancies (37, 38).
The ZNF676 is a transcriptional regulator with an interest-
ing suggested role in telomere homeostasis in humans (39). 
Telomere dysfunction is a common cause and a hallmark of 
cancer that can lead to genomic instability when associated 
with loss of cell cycle control (40). It is unclear how ZNF676 
controls the length of telomeres. Theoretically, it can modify the 
telomere length (a) by directly binding to DNA, and it might 
alter the expression (repression/activation) of genes engaged in 
telomere maintenance and (b) by binding specifically to and sta-
bilizing the G-quadruplex structure of telomeric DNA (39–42). 
However, it was recently demonstrated that pituitary tumors 
do not exhibit alterations in telomeric length, suggesting that 
telomere biology does not play an important role in pituitary 
tumor development (43).
DAPK1 is a positive mediator of gamma-interferon-induced 
programmed cell death with a putative role of metastasis suppres-
sor. DAPK1 expression silencing due to promoter methylation 
has been frequently found in lung cancer, in which cells with lack 
of DAPK1 expression appear to be more invasive and more meta-
static (41). This gene was also found to be frequently overmethyl-
ated in head and neck cancers and in immunodeficiency-related 
lymphomas (44–46).
TIMP2 is a tissue inhibitor of the matrix metalloproteinase 
family (MMP) and has been studied in several human tumors, 
in which a negative correlation between TIMP2 expression and 
aggressiveness/malignancy was demonstrated (47). Recently, the 
predictive roles of MMP9 and TIMP1 and 2 in the invasiveness 
of prolactinomas were studied, and higher MMP9 expression 
and underexpression of TIMP2 were found in invasive tumors 
(48). Therefore, it is possible that TIMP2 could also be a potential 
marker of invasion in corticotrophinomas.
Among our differentially expressed genes, some corroborated 
published studies that compared gene expression of normal pitui-
tary tissue and pituitary adenomas: the overexpression of CCND1 
and underexpression of CDKN2A. CCND1 encodes the cyclin D1 
protein, which together with other cyclins, acts in the regulation 
of cyclin-dependent kinases (CDKs). The activation or inactiva-
tion of kinases mechanisms is often associated with cell cycle 
(49). Additionally, the overexpression of CCND1 is known to be 
present in many neoplasms, malignant, and non-malignant, and 
it is considered one of the most important tumorigenic factors 
(19, 50). Despite this, few studies investigated its role in pituitary 
8de Araújo et al. Transcriptome Analysis of Invasive and Non-invasive Corticotrophinomas
Frontiers in Endocrinology | www.frontiersin.org March 2017 | Volume 8 | Article 55
FigUre 2 | continued
FigUre 2 | continued 
heat map and hierarchical clustering of 168 differently expressed 
genes between invasive and non-invasive corticotrophinomas 
showing that these groups exhibit a distinct gene expression profile. 
Different genes are represented in different rows and different experiments in 
different columns. The colored bar above the heat map (horizontal dimension) 
indicates the grouping variable—green for non-invasive (n = 9) and orange 
for invasive tumors (n = 3). The normalized expression value of each gene is 
color coded, from red for higher expressions to green for lower expressions 
and genes with no change in expression are represented in black.
adenomas, only two studies have observed the overexpression of 
CCND1 in adenomas compared with normal pituitary tissue. In 
addition, the increased expression of cyclin D1 was associated 
with a greater recurrence of the disease (50, 51). The CDKN2A 
also encodes a CDK inhibitor, p16, directly involved in cell cycle 
control (52). It has been demonstrated that CDKN2A meth-
ylation occurs in the entire locus, in all subtypes and pituitary 
tumors. In addition, the dysfunction of p16 was associated with 
the increased size of these tumors (53). Another study went 
further and demonstrated that functional corticotrophinomas 
exhibited an expression of this gene up to four times higher than 
non-functioning adenomas. The authors suggested that this 
result could explain why functional corticotrophinomas tend 
to be smaller than other types of adenomas (54). Corroborating 
these correlations, in our cohort of invasive corticotrophinomas, 
with underexpression of CDKN2A, the mean tumor size was 
significantly higher (27.7 ± 11.2 mm) than in the non-invasive 
corticotrophinomas (10.9 ±  4.8  mm), even when we consider 
only the size of MACs (15.40 ± 4.04 mm).
Interestingly, in our study, both the pituitary tumor-transform-
ing gene 1 (hPTTG1) and VEGF were found to be underexpressed 
in the invasive group. hPTTG1 encodes a mammalian securin 
found to be overexpressed in several tumors and to transform 
cells in vitro and in vivo, and VEGF is the most frequently studied 
angiogenic factor that is involved in endothelial cell prolifera-
tion, vascular permeability, and cell motility (8, 20). It has been 
reported hPTTG1 overexpression in pituitary adenoma (21, 22) 
and its positive correlation with invasiveness (23, 55). As these 
studies used different methodologies and they included non-
corticotroph pituitary adenoma, it might explain the reason for 
the discrepancy in our results.
In a similar manner, FGFR4 did not show significant expres-
sion difference between invasive and non-invasive corticotro-
phinomas. It is important to notice that hPTTG1 and FGFR4 
overexpression was previously positively correlated with elevated 
Ki-67 nuclear proliferation index in pituitary adenomas (>3%) 
(12, 23). However, in our study Ki-67 did not indicate aggressive-
ness; therefore, this might contribute to the difference obtained 
in microarray expression results.
Likewise, CDN1B that encodes p27kip1 protein, member of 
the Cip/Kip family of CDK inhibitors, was overexpressed in 
our cohort of invasive corticotrophinomas, although it has been 
demonstrated that the loss of expression of CDN1B may result in 
pituitary hyperplasia and tumorigenesis (19). Therefore, the rea-
son for this discrepancy of our result with the previous published 
is not clear.
It is noteworthy to mention that, in the presence of the overex-
pression of CCND2 and ZNF676, and underexpression of DAKP1 
and TIMP2, patients from the invasive group demonstrated a 
higher mean of presurgical ACTH (102.3 ± 52.2 pg/mL, normal 
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TaBle 6 | Twenty most significantly over- or underexpressed genes in invasive versus non-invasive corticotrophinoma groups.
gene symbol Description Fold change (linear) anOVa FDr
p-Value p-Value
IFI44 Interferon-induced protein 44 43.02 0.00012 0.025879
CCND2 Cyclin D2 27.61 0.00003 0.013711
ZNF676 Zinc-finger protein 676 29.28 0.000198 0.030477
ANGPTL7 Angiopoietin-like 7 15.20 0.000035 0.015151
KCNH8 Potassium voltage-gated channel member 8 10.36 0.000554 0.045037
MGARP NADH dehydrogenase (ubiquinone) 1 8.70 0.00004 0.015427
DHCR24 24-dehydrocholesterol reductase 6.87 7.97E−07 0.004751
PRKD3 Protein kinase D3 6.81 0.000105 0.024751
CEP85L Centrosomal protein 85kda-like 5.77 0.000026 0.013222
SPON1 Spondin 1. Extracellular matrix protein −16.79 0.011393 0.16522
SEPT3 Septin 3 −11.83 0.00009 0.022919
MPPED2 Metallophosphoesterase domain-containing 2 −9.51 0.000086 0.022798
CSGALNACT1 Chondroitin sulfate N-acetylgalactosaminyltransferase 1 −8.20 0.000234 0.031613
DAPK1 Death-associated protein kinase 1 −7.80 0.000037 0.015151
DOCK11 Dedicator of cytokinesis 11 −7.17 0.000299 0.034763
RGS7 Regulator of G protein signaling 7 −6.48 0.00001 0.010564
PEX2 Peroxisomal biogenesis factor 2 −3.57 0.0006 0.046209
TIMP2 TIMP metallopeptidase inhibitor 2 −3.07 0.000178 0.029718
ARNT2 Aryl-hydrocarbon receptor nuclear translocator 2 −2.61 0.000011 0.011139
CDKN2A Cyclin-dependent kinase inhibitor 2A −2.01 0.000344 0.035806
FDR, false discovery rate.
TaBle 7 | list of signaling pathways affected with at least three 
downregulated and/or upregulated genes.
Pathway #Total Downregulated Upregulated
Vitamin D receptor pathway 5 RXRA, CD200, 
TIMP2, CDKN2A
CDKN1B
TGF beta signaling pathway 4 CAV1, MEF2A, 
PIAS1
ZFYVE16
G protein signaling pathways 4 GNAO1, PRKACB, 
AKAP12
PRKD3
DNA damage response (only 
ATM dependent)
3 CDKN2A CDKN1B, CCND2
DNA damage response 3 – FAS, CDKN1B, 
CCND2
G1 to S cell cycle control 3 CDKN2A CCND2, CDKN1B
Focal adhesion 3 CAV1 SEPP1, CCND2
Nuclear receptors 
meta-pathway
3 RXRA CDKN1B, 
SLC39A8
miRNA regulation of DNA 
damage response
3 – FAS, CDKN1B, 
CCND2
range <46 pg/mL) compared to patients from the non-invasive 
group (51.7  ±  15.9  pg/mL, normal range 50–310  μg/24  h). 
In contrast, patients harboring non-invasive corticotrophi-
nomas presented higher concentrations of urinary cortisol 
(639.6 ±  358.0 μg/24 h) when compared to patients harboring 
invasive corticotrophinomas (406.0 ± 34.8 μg/24 h).
Despite the intrinsic difficulty of handling and obtaining viable 
corticotroph tumor tissue for molecular studies and the low inci-
dence of invasive corticotrophinomas, we were able to use a larger 
cohort of new patients and perform qRT-PCR to the highlighted 
genes. Our validation results corroborated the initial findings 
of the microarray study, as we observed CCND2 and ZNF676 
overexpression and DAPK1 and TIMP2 underexpression.
Since there are no other molecular studies available compar-
ing invasive and non-invasive corticotrophinomas, this study is 
an important contribution to the investigation of the biological 
behavior of these tumors.
cOnclUsiOn
We identified a differential pattern of genetic signature in a 
subgroup of MACs, supporting a genetic influence on the patho-
genesis of corticotrophinomas. This study highlighted genes that 
might contribute for the improvement of molecular diagnosis of 
invasive corticotrophinomas. Additional analysis are necessary 
to evaluate the differential protein expression in a larger cohort, 
therefore they could be used in clinical practice.
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FigUre 3 | relative expression levels (fold change) of CCND2, ZNF676, DAPK1, and TIMP2.
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